Blog Archives

Schwere Nebenwirkungen: Das MS-Arzneimittel Daclizumab (Zinbryta) weltweit vom Markt genommen

02. März 2018 – Daclizumab (Zinbryta) wurde im Mai 2016 in den USA, im Juli 2016 in der Europäischen Union (EU) und im Januar 2017 auch in der Schweiz zur Behandlung der schubförmig auftretenden Multiplen Sklerose auf dem Markt zugelassen. Daclizumab (Zinbryta) ist ein therapeutischer humanisierter monoklonaler Antikörper gegen den Interleukin-2-Rezeptor (genauer: gegen die α-Kette CD25),

Read more ›

Tags: , , , , , , , , ,

Natalizumab (Tysabri)’s Risiko für PML


20. September 2016 – Swissmedic, das Schweizer Heilmittelinstitut, kommuniziert in der Form einer sog. Health Professional Communication (HPC) aktualisierte Massnahmen um dem Risiko von progressiv multifokaler Leukoencephalopathie (PML) unter Therapie mit Natalizumab (Tysabri) entgegenzuwirken.

Read more ›

Tags: , , , ,

BfArM: Strengere kardiovaskuläre Überwachung zu Beginn der Therapie mit Fingolimod [Gilenya] bei Patienten mit schubförmig-remittierend verlaufender Multipler Sklerose

27. Januar 2012 – Das BfArM hat heute mitgeteilt, dass ein “Rote Hand Brief” betreffend Fingolimod [Gilenya] mit untenstehendem Wortlaut von der Firma Novartis Pharma versandt wurde.


Novartis möchte Sie über wichtige zusätzliche Empfehlungen zu mit Fingolimod [Gilenya] informieren. Diese betreffen eine intensivere Überwachung der kardiovaskulären Funktionen innerhalb der ersten 6 Stunden nach Behandlungsbeginn mit Fingolimod [Gilenya],

Read more ›

Tags: , , , ,

thasso: zustände

thasso: kurzmitteilungen

thasso post: magazin

View my Flipboard Magazine.

thasso: kategorien

thasso: archive

thasso: einfacher chat

You must be a registered user to participate in this chat.

  • Tick, tock: How stress speeds up your chromosomes' aging clock December 5, 2019
    Ageing is an inevitability for all living organisms, and although we still don't know exactly why our bodies gradually grow ever more decrepit, we are starting to grasp how it happens.
  • Genome testing for siblings of kids with autism may detect ASD before symptoms appear December 5, 2019
    One of the key priorities of interventions for autism spectrum disorder (ASD) is starting early, with some evidence showing infants as young as seven months old could benefit. Yet, most children in North America aren't diagnosed with ASD until they're over four years of age. New research led by The Hospital for Sick Children (SickKids) […]
  • 2019: the year gene therapy came of age December 5, 2019
    In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering—by editing her genome.
  • Scientists create 'epigenetic couch potato' mouse December 4, 2019
    Why is it that some people love to exercise, and others hate it? Most people would assume it's all due to genetics, but a new Baylor College of Medicine led study in mice shows for the first time that a different molecular level of regulation—epigenetics—plays a key role in determining one's innate drive to exercise. […]
  • Human genetic enhancement might soon be possible—but where do we draw the line? December 4, 2019
    The first genetically edited children were born in China in late 2018. Twins Lulu and Nana had a particular gene—known as CCR5—modified during embryonic development. The aim was to make them (and their descendants) resistant to HIV. By some definitions, this would be an example of human enhancement.